Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
Webcast Details
Apogee Therapeutics' live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7th at 8:00 a.m. ET. The live webcast can be accessed via this link or the Investors section on the Company's website at https://investors.apogeetherapeutics.com/news-events/events. A replay of the webcast will be available following the call.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
[email protected]
Media Contact:
Dan Budwick
1AB
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Bush, Obama and Bono bid farewell to USAID as researchers warn agency's closure means 14m extra deaths
Staff at the U.S. Agency for International Development (USAID) marked their final day on the job on Monday with tributes from two former presidents and a rock legend as new research revealed the stark reality of life without their help. George W Bush, Barack Obama and U2 frontman Bono expressed their thanks to departing employees from the international aid agency in heartfelt video messages as their offices were shuttered under President Donald Trump's 'America First' agenda. Secretary of State Marco Rubio announced in March that 83 percent of USAID's programs would be cut because they did not serve 'the core national interests of the United States,' with the remainder of the agency being folded into his department. But fresh doubt was cast on the wisdom behind that decision by findings published in The Lancet medical journal on the same day staff were saying goodbye, which indicated that 14 million more people will die over the next five years without the humanitarian support USAID once provided. An international team of researchers found the agency's global outreach efforts had prevented 92 million deaths between 2000 and 2021 across 133 countries, saving the lives of 25 million HIV/Aids sufferers, 11 million people with diarrheal diseases, 8 million with malaria and nearly 5 million with tuberculosis. Of the 14 million extra deaths, 4.5 million will be accounted for by children under five, they concluded. Davide Rasella of the Barcelona Institute for Global Health, one of the report's co-authors, called the findings 'striking' and said the likely impact on low and middle-income countries will be 'comparable in scale to a global pandemic or a major armed conflict.' He added that the cuts to USAID 'risk abruptly halting – and even reversing – two decades of progress in health among vulnerable populations.' The agency, founded in 1961, managed a budget of $35bn last year, according to the Congressional Research Service, and was involved in everything from running health clinics and building schools to more mundane but vital tasks like distributing nutrition pouches, mosquito nets and chlorine tablets. 'You've shown the great strength of America through your work, and that is our good heart,' Bush told the outgoing workers on Monday, according to The New York Times, also thanking them for enacting his signature Emergency Plan for Aids Relief. 'Is it in our interest that 25 million people who would have died now live? I think it is,' he said. 'On behalf of a grateful nation, thank you for your hard work, and God bless you.' Obama, in turn, attacked the decision to close USAID as 'a colossal mistake' and lamented: 'Ending your presence and your programs out in the world hurts the most vulnerable, and it hurts the United States. 'To many people around the world, USAID is the United States.' Bono, well known for his advocacy for developing nations, chose to deliver his message in rhyme and said: 'They called you crooks – when you were the best of us, there for the rest of us. And don't think any less of us, when politics makes a mess of us. 'It's not left-wing rhetoric to feed the hungry, heal the sick. If this isn't murder, I don't know what is.' The Lancet's forecast appeared to bear out his assessment and the research it published is by no means the only study to have anticipated such a bleak outcome from USAID's closure. A Boston University model, for instance, has put the human cost of its demise in even more shocking terms: 88 deaths per hour. Amira Albert Roess, a professor of global health and epidemiology at George Mason University, told NBC News it was the speed of the Trump administration's decision that is so dangerous. 'For better or for worse, some of the USAID-funded clinics in some areas, they were the main source of care,' she said. 'If you wanted to reduce USAID funding, it could have been done in a more gradual manner, instead of this sudden – and really, in a lot of places, overnight – shuttering of clinics.' Roess said she was particularly concerned by the abrupt closure of HIV clinics and warned: 'If you miss a dose or multiple doses, as was the case with lots of individuals, that's creating a situation where the individual can start to deteriorate fairly rapidly.' In May, Microsoft co-founder Bill Gates announced he would be bringing forward the charitable donation of $200bn from his personal fortune in order to help meet the shortfall and continue the fight against deadly diseases around the world. In doing so, Gates derided his fellow tech boss Elon Musk for his part in the cuts as the then-leader of Trump's Department of Government Efficiency (DOGE).
Yahoo
23 minutes ago
- Yahoo
Workers union announces tentative agreement with King Soopers after days of negotiations
The union that represents thousands of Colorado King Soopers employees announced on Thursday it had reached a tentative agreement on a three-year contract with the company after days of negotiations.
Yahoo
23 minutes ago
- Yahoo
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li BEIJING, July 07, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC ("1Globe") for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, "relief relating to governance outcomes or shareholder votes – are DENIED without prejudice." The Massachusetts ruling marks the fourth unsuccessful legal attempt by either Advantech/Prime Success ("Advantech/Prime") or Vivo Capital (together "the Dissenting Investor Group") to strip SINOVAC common shareholders of their rightful dividend payments. This result follows Advantech/Prime's recently failed petition in New York and Advantech/Prime and Vivo Capital's recently failed petition in Hong Kong – which were repeated attempts to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the Company's payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. The Dissenting Investor Group continues to interfere with the current Board's fiduciary duties to implement the UK Privy Council's unappealable ruling in January 2025. In this ruling, the UK Privy Council deemed the former illegitimate board an "Imposter Board" and handed 1Globe – the investment arm of a cancer-focused global R&D group and SINOVAC's largest shareholder – a victory on all grounds. In addition, the UK Privy Council Judicial Committee, comprising five UK Supreme Court Justices, concluded that there was "nothing unlawful in the conduct of 1Globe" in connection with SINOVAC's 2018 AGM. The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy is crystal clear: (1) block actions taken by the SINOVAC Board to distribute rightful dividend payments to valid SINOVAC common shareholders; (2) protect the ill-gotten gains it stripped from SINOVAC subsidiaries over the past seven years; and (3) regain control of SINOVAC in order to continue to loot the Company. Having failed in the courtroom, the Dissenting Investor Group has decided to instead use deceptive and false stories to attack 1Globe and its founder Dr. Chiang Li, who chairs the current SINOVAC Board. As noted in SINOVAC's proxy materials, Dr. Li is an accomplished clinician, scientist, inventor, entrepreneur and a seasoned executive with international recognitions. Dr. Li and 1Globe have successfully challenged the Dissenting Investor Group's abuse in court for the past seven years and championed the rights and interests of all valid SINOVAC shareholders. During those seven years, The Dissenting Investor Group, in coordination with the former illegitimate board (the "Imposter Former Board"), pursued the following schemes: Privatization attempt at a below-market price in 2016, which would have succeeded had it not been for the efforts of 1Globe (who declined an invite by the Former Management Buyout Group to join and profit from its privatization attempt); Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; Commitment by the Imposter Former Board to invest ~US$139 million of SINOVAC cash into a venture fund managed by Vivo Capital – creating a clear conflict of interest. This would be in addition to the approximately US$100 million SINOVAC has already invested into Vivo Capital funds. US$15 million debt investment into Sinovac Life Sciences Co., Ltd. ("SLS"), a wholly owned subsidiary of SINOVAC, in exchange for a 15% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$1 billion of distributions made to the Dissenting Investor Group. In contrast, SINOVAC common shareholders have received no dividends and haven't been able to trade their shares for the past six years. To add insult to injury, the Imposter Former Board publicly stated in April 2024 in the Company's 2023 20-F that it had "no plan to pay any cash dividends on SINOVAC Antigua's shares in the foreseeable future"; Barrage of baseless and wasteful legal action in 2025, after refusing to accept the Privy Council's non-appealable ruling, with the goal of interfering with the dividend payment unless the Dissenting Investor Group is able to double dip on dividends already received from SLS; Deceptive and disparaging campaign against current SINOVAC board members that is meant to intimidate them and interfere with the stability and function of the current Board. The Dissenting Investor Group's hostile actions, baseless claims and wasteful litigation are evidence that it poses a direct threat to the value of your investment and the future of SINOVAC. Don't let the Dissenting Investor Group, which is working in coordination with SAIF and is represented on SAIF's Reconstituted Imposter Former Board, regain control of the Company. If the Reconstituted Imposter Former Board succeeds, it will put all valid shareholders' future dividend payments at risk – this includes the current Board's announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares, and its adopted policy to issue regular dividends out of surplus cash. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card "AGAINST" Proposal 1 to remove the current Board and "AGAINST" Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
